Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder
Recruiting
N/A
Interventional Study
Bladder Cancer
Urinary Diversion
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 100
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 96 (estimated)
- Sponsor
- Zhujiang Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Bladder cancer is a common malignant tumor of the urinary system, radical resection plus urinary diversion is the first choice of treatment for muscle invasive bladder cancer. Urinary diversion of surgical options related to patient' survival and quality of life.
In 1988, Hautmann firstly reported an orthotopic urinary diversion method: Hautmann neobladder. As the urine can be controlled from the…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Bladder carcinoma in situ, include CIS and T1G3 tumor, muscle invasive bladder cancer(T2/T3N0-1M0)
2. Recurrent bladder cancer
3. Other conditions that have been approved by a urologist for indications for new bladder surgery
4. Had been received intravesical chemotherapy, in…
Contacts